{"title":"Crinecerfont in Adult Congenital Adrenal Hyperplasia","authors":"","doi":"10.1056/nejmc2411263","DOIUrl":null,"url":null,"abstract":"To the Editor: In the phase 3 CAHtalyst trial reported by Auchus et al. (Aug. 8 issue),1 the use of crinecerfont allowed for a greater reduction in the mean daily glucocorticoid dose than placebo (...","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":null,"pages":null},"PeriodicalIF":96.2000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New England Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1056/nejmc2411263","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
To the Editor: In the phase 3 CAHtalyst trial reported by Auchus et al. (Aug. 8 issue),1 the use of crinecerfont allowed for a greater reduction in the mean daily glucocorticoid dose than placebo (...
期刊介绍:
The New England Journal of Medicine (NEJM) stands as the foremost medical journal and website worldwide. With an impressive history spanning over two centuries, NEJM boasts a consistent publication of superb, peer-reviewed research and engaging clinical content. Our primary objective revolves around delivering high-caliber information and findings at the juncture of biomedical science and clinical practice. We strive to present this knowledge in formats that are not only comprehensible but also hold practical value, effectively influencing healthcare practices and ultimately enhancing patient outcomes.